Lamictal in the Treatment of Post-Herpetic Neuralgia

• Status: Terminated
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To assess the efficacy of Lamictal for the treatment of pain and reduction of allodynia in patients with post herpetic neuralgia.

• Phase: Phase 2/Phase 3

Details

• Lead Sponsor: George Washington University
• Collaborator: GlaxoSmithKline
• Treatments: Gabapentin; Lamotrigine

Criteria

Inclusion Criteria:

• All patients will be over the age of 18,

• Need to have a diagnosis of Post-Herpetic Neuralgia,

• Minimum of 4 on the Likert Pain Scale,

• If currently taking TCA and/or Gabapentin, need to have been on stable dose for minimum of 4 weeks

Exclusion Criteria:

• Currently on any antiepileptic drugs (AED), except for Gabapentin.

• Currently taking opioid or unwilling to washout prior to the study,

• Pregnant and lactating,

• Have active severe systemic disease,

• History of Stevens-Johnson syndrome or TEN,

• Clinically significant abnormal lab values,

• Known drug allergy to Lamictal,

• Patients on Fibrates (Tricor and Lopid),

• History of major psychiatric disturbance and substance abuse.

• Valproate due to increase chances of severe rash,

• Lidocaine Patch,

• Use of hormonal contraceptives (birth control pills, patch, ring, injection)